Artificial intelligence (AI), specifically Natural Language Processing (NLP), is revolutionizing pharmaceutical regulatory documents by facilitating automated extraction of data, real-time regulatory change monitoring, and standardization of submissions like the Common Technical Document (CTD), enhancing accuracy and efficiency over the conventional manual approach. In spite of these advantages, obstacles exist in dealing with dynamic regulatory needs, intricate legal and scientific terminology, algorithmic uncertainty, and issues relating to data quality, ethics, and compliance, particularly when NLP technologies become more integrated into Software as a Medical Device. For an investigation of these concerns, this narrative review reviewed regulatory materials from authorities such as the U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare Products Regulatory Agency, and international organizations such as the World Health Organization and co-operation and development, complemented by a subject-specific search of Scopus, PubMed, and Google Scholar (2015–2025). English-language peer-reviewed articles, regulatory guidelines, and industry reports relevant to the topic were included and thematically synthesized under opportunities, challenges, ethical issues, and regulatory views. The results indicate that despite the immense potential of AI/NLP solutions to improve regulatory effectiveness and transparency, they pose intricate technical, regulatory, ethical, and operational issues requiring harmonized international standards, stringent validation frameworks, and multistakeholder engagement to deploy safely and effectively in regulatory science.
Pawar HB, Neelanshu, Bhat GM, Srikanth A, Muragundi PM. Challenges of using Artificial Intelligence (Natural Language Processing) tools for regulatory documentation. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2026.267918
1. Ajmal CS, Yerram S, Abishek V, Nizam VPM, Aglave G, Patnam JD, et al. Innovative approaches in regulatory affairs: leveraging artificial intelligence and machine learning for efficient compliance and decision-making. AAPS J. [cited 2025 May 27]. Available from: https://link.springer.com/article/10.1208/s12248-024-01006-5
2. European Medicines Agency (EMA). Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle. 2024. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf
3. American Pharmaceutical Review. Advancing regulatory compliance with natural language processing. American Pharmaceutical Review. The Review of American Pharmaceutical Business & Technology [Internet]. [cited 2025 May 27]. Available from: https://www.americanpharmaceuticalreview.com/Featured-Articles/607985-Advancing-Regulatory-Compliance-with-Natural-Language-Processing/
4. Licari D, Comandè G. ITALIAN-LEGAL-BERT models for improving natural language processing tasks in the Italian legal domain. [cited 2025 May 27]. Available from: https://www.sciencedirect.com/science/article/pii/S0267364923001188
5. U.S. Food and Drug Administration (FDA). FDA releases artificial intelligence/machine learning action plan. FDA [Internet]. [cited 2025 May 27]. Available from: https://www.fda.gov/news-events/press-announcements/fda-releases-artificial-intelligencemachine-learning-action-plan
6. European Medicines Agency (EMA). Artificial intelligence. European Medicines Agency (EMA) [Internet]. [cited 2025 May 27]. Available from: https://www.ema.europa.eu/en/about-us/how-we-work/data-regulation-big-data-other-sources/artificial-intelligence
7. U.S. Food and Drug Administration. Artificial intelligence and machine learning in drug development: discussion paper and action plan [Internet]. Silver Spring (MD): FDA; 2023 [cited 2025 Aug 30]. Available from: https://www.fda.gov/media/167973/download
8. European Medicines Agency (EMA). Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle [Internet]. Amsterdam: EMA; 2023 [cited 2025 Aug 30]. Available from: https://www.ema.europa.eu/system/files/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle-en.pdf
9. World Health Organization (WHO). Ethics and governance of artificial intelligence for health [Internet]. Geneva: WHO; 2023 [cited 2025 Aug 30]. Available from: https://www.who.int/publications/i/item/9789240029200
10. International Council for Harmonisation (ICH). M4 QCommon technical document for the registration of pharmaceuticals for human use – quality. Geneva: ICH; 2002.
11. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
12. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019;17:195. [cited 2025 May 27]. Available from: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1426-2
13. Lieber T, Voskuil R, Mol P, Härmark L. Natural language processing for automated triage and prioritization of individual case safety reports. Front Drug Saf Regul. 2023 [cited 2025 Sep 4]. Available from: https://www.frontiersin.org/articles/10.3389/fdsfr.2023.1120135/full
14. Peer AI. Transforming regulatory bottlenecks into strategic accelerants. Peer AI Blog; 2025 [cited 2025 Sep 4]. Available from: https://getpeer.ai/blog/ai-in-cmc-medical-writing-transforming-regulatory-bottlenecks-into-strategic-accelerants
15. ICH Harmonised Tripartite Guideline. Guidance for Industry: M4Q – The CTD – Quality. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), 2003.
16. MHRA (UK Medicines and Healthcare Products Regulatory Agency). GXP Data Integrity Guidance and Definitions [Internet]. 2018 [cited 2025 May 27]. Available from: https://www.gov.uk/government/publications/guidance-on-gxp-data-integrity
17. General data protection regulation (GDPR). EUR-Lex [Internet]. [cited 2025 May 27]. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=LEGISSUM%3A310401_2
18. Chatila R, Havens JC. The IEEE global initiative on ethics of autonomous and intelligent systems. In: Aldinhas Ferreira MI, Silva Sequeira J, Singh Virk G, Tokhi MO, E. Kadar E, editors. Robotics and well-being [Internet]. Cham: Springer International Publishing; 2019 [cited 2025 May 27]. pp. 11–6. (Intelligent Systems, Control and Automation: Science and Engineering; Vol. 95). Available from: http://link.springer.com/10.1007/978-3-030-12524-0_2
19. Ribeiro MT, Singh S, Guestrin C. Peeking inside the black-box: a survey on explainable artificial intelligence (XAI). IEEE Access. 2018;6:52138–60. doi: https://doi.org/10.1109/ACCESS.2018.2870052
20. European Medicines Agency. Good pharmacovigilance practices (GVP). European Medicines Agency (EMA) [Internet]. 2025 [cited 2025 May 27]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp
21. Purdie FP. Data integrity and compliance with CGMP guidance for industry. U.S. Food and Drug Administration. 2017. Available from: https://www.fda.gov/files/drugs/published/Data-Integrity-and-Compliance-With-Current-Good-Manufacturing-Practice-Guidance-for-Industry.pdf
22. International Society for Pharmaceutical Engineering. GAMP 5 a risk based approach to a risk-based approach to compliant GxP compliant GxP computerized systems [Internet]. 2008. [cited 2025 May 27]. Available from: https://www.academia.edu/36720108/GAMP_5_A_Risk_Based_Approach_to_A_Risk_Based_Approach_to_Compliant_GxP_Compliant_GxP_Computerized_Systems
23. Wu Y, Liu Z, Wu L, Chen M, Tong W. BERT-based natural language processing of drug labeling documents: a case study for classifying drug-induced liver injury risk. Front Artif Intell. 2021;4:729834. [cited 2025 May 27]. Available from: https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2021.729834/full?utm_source=chatgpt.com
24. International Council for Harmonisation. ICH Q1A (R2) Stability testing of new drug substances and drug products - Scientific guideline. European Medicines Agency (EMA) [Internet]. 2003. [cited 2025 May 27]. Available from: https://www.ema.europa.eu/en/ich-q1a-r2-stability-testing-new-drug-substances-drug-products-scientific-guideline
25. Kuo TT, Kim HE, Ohno-Machado L. Blockchain distributed ledger technologies for biomedical and health care applications. J Am Med Inform Assoc. 2017;24(6):1211–20. [cited 2025 May 27]. Available from: https://academic.oup.com/jamia/article/24/6/1211/4108087?login=true
26. Ribeiro MT, Singh S, Guestrin C. “Why Should I Trust You?” Explaining the predictions of any classifier. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining [Internet]. 2016 [cited 2025 May 27]. Available from: https://dl.acm.org/doi/10.1145/2939672.2939778
27. European Parliament and Council of the European Union. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Available from: http://data.europa.eu/eli/reg/2016/679/oj
28. Publications Office of the EU. General data protection regulation (GDPR) [Internet]. 2018 [cited 2025 May 27]. Available from: https://op.europa.eu/en/publication-detail/-/publication/e899a0de-be12-405c-84ae-34e8a22d6acd/language-en
29. Edemekong PF, Annamaraju P, Afzal M, Haydel MJ. Health Insurance Portability and Accountability Act (HIPAA) Compliance. StatPearls Publishing; 2024 [cited 2025 May 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500019/
30. Centers for Disease Control and Prevention (CDC). Health Insurance Portability and Accountability Act of 1996 (HIPAA) [Internet]. 1996 [cited 2025 May 27]. Available from: https://www.cdc.gov/phlp/php/resources/health-insurance-portability-and-accountability-act-of-1996-hipaa.html
31. U.S. FDA. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan; 2021. Available from: https://www.fda.gov/media/145022/download
32. U.S. FDA. Using artificial intelligence and machine learning in the development of drug and biological products. Discussion Paper and Request for Feedback. 2023 Available from: https://www.fda.gov/media/167973/download
33. Covington Digital Health. EMA releases reflection paper on AI/ML in the medicinal product lifecycle [Internet]. 2023 [cited 2025 May 27]. Available from: https://www.covingtondigitalhealth.com/2023/07/ema-releases-reflection-paper-on-ai-ml-in-the-medicinal-product-lifecycle/
34. International Council for Harmonisation. ICH M4 Common technical document (CTD) for the registration of pharmaceuticals for human use - organisation of CTD - Scientific guideline. European Medicines Agency (EMA) [Internet]. 2003. [cited 2025 May 27]. Available from: https://www.ema.europa.eu/en/ich-m4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-scientific-guideline
35. Obermeyer Z, Powers BW, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447–53. doi: https://doi.org/10.1126/science.aax2342
36. World Intellectual Property Organization (WIPO). Revised Issues Paper on Intellectual Property Policy and Artificial Intelligence [Internet]. 2023 [cited 2025 May 27]. Available from: https://www.wipo.int/meetings/en/doc_details.jsp?doc_id=499504
37. Deloitte UK. AI risk and approaches to global regulatory compliance [Internet]. 2025 [cited 2025 May 27]. Available from: https://www.deloitte.com/uk/en/Industries/technology/perspectives/ai-risk-and-approaches-to-global-regulatory-compliance.html
38. European Medicines Agency. Guideline on computerized systems and electronic data in clinical trials. 2025. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-computerised-systems-electronic-data-clinical-trials_en.pdf
39. NAVEX. The evolving AI regulatory landscape in Asia: what compliance leaders need to know. NAVEX. 2025 [cited 2025 May 27]. Available from: https://www.navex.com/en-us/blog/article/the-evolving-ai-regulatory-landscape-in-asia-what-compliance-leaders-need-to-know/
40. World Health Organization (WHO). Ethics and governance of artificial intelligence for health [Internet]. Geneva: WHO; 2023 [cited 2025 May 27]. Available from: https://www.who.int/publications/i/item/9789240029200
Year
Month